I 
117TH CONGRESS 
1ST SESSION H. R. 3778 
To establish a program to oversee the global COVID–19 response and prepare 
for future pandemics, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 8, 2021 
Mr. KRISHNAMOORTHI (for himself, Ms. JAYAPAL, Mr. KHANNA, Mr. COHEN, 
Mr. PAYNE, Mr. GRIJALVA, Ms. NORTON, Mr. CARSON, and Ms. ROSS) 
introduced the following bill; which was referred to the Committee on 
Foreign Affairs, and in addition to the Committee on Energy and Com-
merce, for a period to be subsequently determined by the Speaker, in 
each case for consideration of such provisions as fall within the jurisdic-
tion of the committee concerned 
A BILL 
To establish a program to oversee the global COVID–19 
response and prepare for future pandemics, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Nullifying Opportuni-
ties for Variants to Infect and Decimate Act’’ or the 
‘‘NOVID Act’’. 
VerDate Sep 11 2014 
06:58 Jul 03, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H3778.IH
H3778
pbinns on DSKJLVW7X2PROD with BILLS
SEC. 2. SENSE OF CONGRESS. 
It is the sense of Congress that— 
(1) the United States has made tremendous 
progress towards ending the COVID–19 pandemic 
within its borders, thanks to an unprecedented and 
highly successful vaccination campaign spearheaded 
by the Biden administration; 
(2) beyond those borders, the pandemic con-
tinues to rage unchecked across much of the world 
as global vaccination efforts have struggled to keep 
pace; 
(3) if current trends continue, many middle-in-
come countries may not achieve widespread vaccina-
tion until late 2022, and the world’s poorest nations 
will likely not reach widespread vaccination coverage 
before 2023, if at all; 
(4) this situation threatens progress toward 
ending the COVID–19 pandemic here in the United 
States, as unchecked transmission of COVID–19 
gives rise to new variants, many of which show vac-
cine-resistance; 
(5) the most concerning of these variants has 
been shown to reduce vaccine efficacy by as much as 
20 to 40 percent; and 
(6) to protect American citizens from the emer-
gence of new vaccine-resistant coronavirus variants 
VerDate Sep 11 2014 
06:58 Jul 03, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H3778.IH
H3778
pbinns on DSKJLVW7X2PROD with BILLS
and to prevent the kind of humanitarian catastrophe 
currently occurring in South Asia, South America, 
and elsewhere, the United States should take up the 
mantle of global leadership in the fight to end the 
COVID–19 pandemic. 
SEC. 3. PANDEMIC PREPAREDNESS AND RESPONSE PRO-
GRAM. 
(a) ESTABLISHMENT.—There is established the 
‘‘Pandemic Preparedness and Response Program’’ (in this 
Act referred to as the ‘‘Program’’) to be responsible for 
and provide oversight over the United States government- 
wide global health response to the COVID–19 pandemic 
and protect Americans from the emergence of COVID– 
19 variants and other pathogens with pandemic potential. 
(b) DIRECTOR.—The Director of the Program shall 
be appointed by the President. The Director shall be re-
sponsible for coordinating among the Federal departments 
and agencies listed in subsection (c)(1) and coordinating 
the role of the United States in the work of international 
non-governmental organizations, development banks, civil 
society, and foreign governments, with respect to the glob-
al health response to the COVID–19 pandemic and the 
prevention of the emergence of variants or of other patho-
gens with pandemic potential. 
VerDate Sep 11 2014 
06:58 Jul 03, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H3778.IH
H3778
pbinns on DSKJLVW7X2PROD with BILLS
(c) FEDERAL DEPARTMENTS AND AGENCIES.—The 
Federal departments and agencies listed in this subsection 
are the following: 
(1) The Department of State. 
(2) The United States Agency for International 
Development. 
(3) The Centers for Disease Control and Pre-
vention. 
(4) The Food and Drug Administration. 
(5) The Biomedical Advanced Research and De-
velopment Authority and the Health Resources and 
Services Administration of the Department of 
Health and Human Services. 
(6) The Department of Defense. 
(7) The Peace Corps. 
(8) The Department of Labor. 
(9) Any other department or agency the Presi-
dent determines appropriate. 
(d) COMPREHENSIVE STRATEGY.—Not later than 30 
days after the date of the enactment of this Act, the Direc-
tor shall develop a comprehensive strategy to end the 
COVID–19 pandemic worldwide, as well as a long-term 
strategy for preventing future pandemics, that includes 
specific achievable goals to accomplish the following with 
respect to the COVID–19 pandemic: 
VerDate Sep 11 2014 
06:58 Jul 03, 2021
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H3778.IH
H3778
pbinns on DSKJLVW7X2PROD with BILLS
(1) With respect to supplies, addressing issues 
relating to the shortages of vaccines, vaccine compo-
nents, and any raw materials necessary to producing 
these articles, as well as other supplies necessary to 
carrying out a global vaccination campaign, to en-
sure that there is an adequate supply of vaccines 
and other necessary articles for all countries (taking 
into account existing manufacturing capacity). 
(2) With respect to delivery, addressing issues 
relating to the end-to-end delivery and administra-
tion of vaccines in low- and middle-income countries 
to ensure that at least 60 percent of the populations 
in the 92 low- and middle-income countries identi-
fied by the COVAX initiative are vaccinated as soon 
as possible and no later than the beginning of the 
second quarter of 2022. 
(3) 
With 
respect 
to 
preventing 
future 
pandemics, addressing issues relating to the coordi-
nation and integration of disease surveillance and 
early-warning systems, harmonizing early crisis re-
sponse measures around the world, and limiting the 
potential for spillover events before they happen. 
(e) AUTHORIZATION OF APPROPRIATIONS.— 
VerDate Sep 11 2014 
06:58 Jul 03, 2021
Jkt 019200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H3778.IH
H3778
pbinns on DSKJLVW7X2PROD with BILLS
(1) AUTHORIZATION.—There is authorized to 
be appropriated $34,000,000,000 to carry out the 
Program established under this section. 
(2) COORDINATION.—Amounts made available 
to any Federal department or agency for providing 
global health assistance or other forms of foreign as-
sistance are also authorized to be made available to 
the Program and shall be subject to the oversight 
and coordination of the Director. 
(3) SENSE OF CONGRESS.—It is the sense of 
Congress that— 
(A) approximately $25,000,000,000 of the 
amount appropriated pursuant to the authoriza-
tion under paragraph (1) should be made avail-
able to scale vaccine manufacturing capacity 
and produce vaccines; 
(B) approximately $8,500,000,000 of such 
funds should be made available to cover the 
cost of end-to-end delivery and administration 
of vaccines in target countries; and 
(C) approximately $500,000,000 should be 
made available to establish a global disease sur-
veillance network to protect against future 
pandemics. 
VerDate Sep 11 2014 
06:58 Jul 03, 2021
Jkt 019200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H3778.IH
H3778
pbinns on DSKJLVW7X2PROD with BILLS
SEC. 4. IMPLEMENTATION OF COMPREHENSIVE STRATEGY. 
(a) IMPLEMENTATION.—In implementing the strat-
egy developed pursuant to section 3(d)— 
(1) the Director of the Program shall— 
(A) ensure the immediate release of the 
80,000,000 doses of vaccine that the United 
States has already committed to send abroad; 
(B) reassess the United States vaccine 
stockpile with regard to domestic vaccination 
objectives and trends to determine whether fur-
ther vaccines can be sent abroad; 
(C) coordinate with the Biomedical Ad-
vanced Research and Development Authority of 
the Department of Health and Human Services 
(BARDA) to rapidly scale manufacturing ca-
pacity around the world, both in the United 
States and in regional manufacturing hubs, to 
whatever degree necessary and wherever nec-
essary, to produce 8,000,000,000 vaccine doses 
as soon as possible, in addition to existing man-
ufacturing capacity; 
(D) consider the potential benefit of re-
gional manufacturing hubs in South America, 
Africa and South Asia for the future of global 
health more generally, and especially the poten-
tial benefit for addressing future pandemics 
VerDate Sep 11 2014 
06:58 Jul 03, 2021
Jkt 019200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H3778.IH
H3778
pbinns on DSKJLVW7X2PROD with BILLS
through the surveillance network implemented 
pursuant to paragraph (3); 
(E) encourage and facilitate technology 
sharing and the licensing of intellectual prop-
erty as much as is necessary to ensure an ade-
quate and timely supply of necessary articles; 
(F) in collaboration with COVAX, ensure 
equitable access to vaccines, especially those 
produced through the efforts of BARDA and 
the Program as described in subparagraph (3) 
and paragraph (2); 
(G) work with international partners to 
provide enough vaccines to lower- and middle- 
income countries to fully vaccinate at least 60 
percent of their respective populations, with 
special attention to the 92 lower- and middle- 
income countries identified by the COVAX ini-
tiative as being the most in need of assistance; 
and 
(H) consider the central and necessary role 
that community engagement and public aware-
ness will play in ensuring the voluntary uptake 
of vaccines by at least 60% of the populations 
in target countries; 
(2) the Program shall— 
VerDate Sep 11 2014 
06:58 Jul 03, 2021
Jkt 019200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H3778.IH
H3778
pbinns on DSKJLVW7X2PROD with BILLS